175results about How to "Reduce systemic side effects" patented technology

The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated / polyalkylene oxide conjugated antigen-binding protein are also described and claimed.

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention provides compounds of formula I:wherein a, b, c, m, p, s, t, W, Ar1, X1, R1, R2, R3, R4, R6, and R7 are as defined specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

The present invention provides ophthalmic formulations of fluticasone that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and / or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and / or allergic conjunctivitis in a subject in need of such treatment by topical application of the fluticasone formulations of the invention directly to the eye.

This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

The invention provides an embolism material composition as well as preparation method and use thereof, the embolism material composition is prepared from reactant raw materials, wherein the reactant raw materials comprise a biocompatibility material, a roentgenopaque substance and a magnetic resonance imaging substance, the roentgenopaque substance and the magnetic resonance imaging (MRI) substance are covered by the biocompatibility material. The embolism material composition not only can be directly detected by an X-ray image device, but also can be directly detected by the MRI, so that a doctor can select a detection method according to self condition of a patient and the medical device condition.

The invention relates to the technical field of medicament delivery by a carrier, in particular to a lung targeting medicament carried proliposome used for injection and an application method thereof. Solid dispersion technology is adopted to obtain solution A by dissolving active medicament, phospholipid liposome, cholesterol liposome, surface active agent and acid type carrier in absolute ethyl alcohol or the mixed solvent of absolute ethyl alcohol and absolute ether; active carbon which is used for injection and has the volume being 0.1-1% of the volume of the solution A is added into the solution A; stirring, standing and filtering of the solution by a millipore filter are carried; therefore, aseptic solution B free of pyrogen is obtained; aseptic additives are added into the solution B under an aseptic condition; organic solvent is removed; and solid granular medicament carried proliposome or powdered medicament carried proliposome are obtained. The invention has the advantages that the preparation process is simple; the cost is low; the quality is controllable; the stability is good; and the invention is suitable for industrial production. The medicament carried proliposome prepared by effervescency dispersion technology has small and uniform particle diameter, the electric charge ranges from -10mv to -30mv, the proliposome can deliver over 90% medicament to a lung, and remarkable lung targeting effect is achieved, and thus being the best preparation delivering medicament by a carrier for treating lung diseases.

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, s, t, Ar1, R1, R2, R3, R4, R6, R7, R8, and W are as defined in the specification. The compounds of formula I are mescaline receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention provides compounds of formula I:wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

This invention belongs to chemistry pharmaceutical field and relates to a medication transfer system, especially relates to an agglutinin masked medication-load transfer mechanism transferring from nose to brain. This invention comprises medication carrier nanograin, vesicle or lipid body surface finish agglutinin. By using the transfer system, resort time of medication-load system on nasal mucosa can be prolonged, dielectric mucosa absorb the medication-load system and selectively deliver small molecular chemistry medication, diagnosis medication, polypeptide proteins and gene medication into brain. This invention can deliver more medication into brain and relatively decrease medication in outer tissue, so it can depress toxic action at every pore while toning up prevention, cure and diagnosis effect of backbone diseases.

The invention discloses an intelligent cerebral stroke drug carrier for ROS (reactive oxygen species) response and a preparation method of the drug carrier. The carrier is a nano vesicle, hydrophobic boric acid ester is grafted to hydrophilic glucan framework to form amphiphilic block copolymers, the amphiphilic block copolymers serve as carrier materials to prepare the nano vesicle, and the nano vesicle encapsulates neuroprotective agents NR2B9C. The preparation method includes the steps: performing covalent grafting for the boric acid ester and glucan; preparing a nano vesicle carrier by grafting reaction carrier materials in an automatically filling manner; encapsulating the neuroprotective agents NR2B9C in the nano vesicle carrier. The weight ratio of the boric acid ester and the glucan is 10: (5-25), the carrier easily responds degradation of ROS mediation, so that drugs rapidly release at cerebral ischemia lesion positions, and release in non-lesion areas is decreased, so that the neuroprotective agents are more safely and effectively transmitted in intracerebral target areas.

The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin / mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and / or lower effective maintenance doses, and / or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

The invention provides an aluminum adjuvant used as a vaccine vector. The adjuvant is characterized in that a PEG derivative bio-material and aluminum are compounded to form nano-particles, so that the property of strong Th2 body fluid immunologic adjuvant of aluminum salt is maintained, and the adjuvant can be efficiently transferred to draining lymph nodes in the body and can be easily ingested by dendritic cells to perform effective cross-presentation and induce cellular immunologic response. The aluminum adjuvant has strong Th1 immunologic response.

The invention relates to the field of Chinese medicine preparation, in particular to a method for preparing tripterine nano structure lipid carrier containing traditional Chinese medicine monomer and application of the tripterine nano structure lipid carrier in preparation of transdermal drugs used for treating psoriasis, rheumatoid arthritis, skin cancer and breast cancer. The tripterine nano structure lipid carrier is characterized by comprising the following components in parts by weight: 1 part of tripterine, 5-100 parts of mixed lipid, 0.5-10 parts of phospholipid, 0.1-15 parts of poloxamer-188 and 0.5-10 parts of vitamin E and tocopherol polyethylene glycol succinate, wherein the mixed lipid is composed of solid lipid monoglycerine and liquid lipid octylic acid / caprin according to the weight ratio of 1: 0.1-10: 1. Tripterine is prepared into the nano structure lipid carrier, the tripterine nano structure lipid carrier in a semi-solid or liquid preparation form is applied in a transdermal way, bioavailability of the tripterine can be improved, toxic response of tripterine can be reduced, and the nano structure lipid carrier provided by the invention has great clinical application value in the improvement of the treatment effect of tripterine.

This invention provides compounds of formula I:wherein a, b, c, d, m, n, p, s, t, Ar1, R1, R2, R3, R4, R6, R7, R8, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

The invention belongs to the technical field of medicine, and provides an injectable PLGA porous composite microsphere preparation embedded with BMP-2 containing particles. A drug-carrying particle is formed by wrapping BMP-2 with hydrophilic materials such as chitosan, collagen or albumin; a microsphere with a 3D porous structure is constructed by the drug-carrying particle and a porous microsphere material PLGA; the drug-carrying particle is embedded inside the porous microsphere. The invention also provides a preparation method of the porous composite microsphere preparation, and an application in preparation of a repair material for defects of bone or cartilage tissue. The porous composite microsphere preparation of the invention can not only realize slow release of drugs at an administration site, but also facilitate proliferation and differentiation of porous supports of seed cells.

The invention discloses embolization particles developable under X-rays. The particles contain a biocompatible material and iodized oil, and the iodized oil is coated by the biocompatible material to form microcapsule particles. The particles have high biocompatibility, can be monitored in embolization, and are convenient for checking the embolization effect after embolization, and the like; during entrapment of medicaments, the medicaments can be released slowly from the particles; relatively high medicament concentration can be kept for a long time on an embolization part; and compared with perfusion treatment, the embolization particles have the advantages: the toxic and side effects of medicaments on a whole body can be lowered, and treatment effect of embolization can be improved. Moreover, a preparation process of the embolization particles is simple, has low cost, and is suitable for large-scale industrial production.

The invention discloses a construction method of a targeted nano particle transmission system for cancer diagnosis and treatment. The nano particle transmission system loaded with superparamagnetic ferroferric oxide and antineoplastic medicaments is constructed by being mediated by a single chain antibody. The antineoplastic medicaments are delivered to target sites in the whole body in a targeted medicament administration mode so as to treat cancers; target spots are identified by antibody-antigen high specificity combination effects; the antineoplastic medicaments can be transferred in vivoand have active targeting performance; and medicinal effects can be improved, and the toxic or side effects of the antineoplastic medicaments on normal tissues can be reduced. Meanwhile, the system can also be used as a nuclear magnetic resonance imaging technology contrast agent so as to improve the accuracy of monitoring the tumor variation conditions at the target sites in real time.

The invention relates to an intravenous oncolytic virus preparation and a preparation method thereof. The method performs transfection of a targeting polypeptide gene to a eukaryotic cell, and displays the targeting polypeptide on a cell membrane to obtain the gene engineering reconstructed cell strain capable of stably expressing the targeting polypeptide, The cell strain is used to extract nano-sized cell membrane vesicles with a uniform size, and then the oncolytic virus (OV) is loaded into the cell membrane vesicles with engineering reconstruction to synthesize an intravenous oncolytic virus complex which can be targeted for tumor delivery. The intravenous oncolytic virus preparation encapsulates the oncolytic virus in the cell membrane vesicles, and can effectively reduce the neutralizing effect of a neutralizing antibody on the oncolytic virus in the body, the cell membrane vesicle has targeting performance after gene engineering reconstruction, can achieve targeted delivery of the oncolytic virus and enrichment at the tumor site, and reduces the systemic side effects of the oncolytic virus.

The invention provides polyvinyl alcohol magnetic particles as well as a preparation method and an application of the polyvinyl alcohol magnetic particles. The polyvinyl alcohol magnetic particles are prepared by reaction among the polyvinyl alcohol magnetic particles, magnetic metal ions and alkaline matter. According to the polyvinyl alcohol magnetic particles, reaction between magnetic materials and hydrogen ions in an acid catalyst can be avoided in the preparation process, thus improving the mangnetic responsiveness and the dispersibility of the polyvinyl alcohol magnetic particles.

This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

The double layer Amlexanox oral patch includes two layers, one adhered Amlexanox layer with Amlexanox in 0.1-10 mg and the other water insoluble protecting layer. The double-layer design reduces the dissolving of medicine to the side opposite to the oral cavity mucous membrane and reduces the bi-directional adhesion between gum and oral cavity mucous membrane, makes most of the medicine penetrate to the ulcer surface and decreases the upset in the oral cavity. The double layer Amlexanox oral patch is located to the ulcer focus, has no irritation to the ulcer surface and acting period as long as 3-4 hr.

A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteriod, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteriod is fluticasone propionate or a solvate thereof. The combination of salmeterol, fluticasone proprionate, and HFA 134a may lower the risk of cardiac arrhythmias, sudden death, or hypercorticism that are sometimes associated with the simultaneous administration of a β2-receptor agonist and an anti-inflammatory corticosteroid.

The invention discloses a sodium alginate microballoon vein suppository containing hemangioma-resisting medicant, a preparation method and an application thereof. The sodium alginate microballoon vein suppository comprises carrier sodium alginate and hemangioma-resisting medicant; the sodium alginate covers the hemangioma-resisting medicant; the weight ratio of the sodium alginate to the hemangioma-resisting medicant is 5:1-60:1; and the hemangioma-resisting medicant is pingyangmycin, sodium morrhuate, carbamide or bleocin. The raw materials used in the invention have favorable mechanical strength, biocompatibility, biological degradability and stability, have no organic solvent, and are basically harmless to functions of hemopoietic system and immune system, thereby suppository can be industrially produced.

A release controllable film coating material targetting to colon is prepared from modified starch through adding the modified starch to coating solvent, and adding plasticizer. Its application is also disclosed.